Close
Help




JOURNAL

Breast Cancer: Basic and Clinical Research

282,058 Journal Article Views | Journal Analytics

Expression of the Androgen Receptor and its Correlation with Molecular Subtypes in 980 Chinese Breast Cancer Patients

Submit a Paper



Publication Date: 06 Dec 2011

Type: Original Research

Journal: Breast Cancer: Basic and Clinical Research

Citation: Breast Cancer: Basic and Clinical Research 2012:6 1-8

doi: 10.4137/BCBCR.S8323

Abstract

Background: Recent studies have shown that androgen displays an inhibitory effect on breast cancer cell lines that express androgen receptor (AR) but not estrogen receptor (ER) and progesterone receptor (PR). We have previously reported that approximately 1/3 of ER negative high grade invasive ductal carcinomas express AR. Thus, AR can serve as a potential therapeutic target for this group of patients.

Aim: Here we investigated AR expression patterns in 980 consecutive breast carcinomas.

Results: We found that (1) AR was expressed more frequently (77%) than ER (61%) and PR (60%) in breast carcinomas; (2) AR expression was associated with ER and PR expression (P < 0.0001), small tumor size (P = 0.0324) and lower Ki-67 expression (P = 0.0013); (3) AR expression was found in 65% of ER negative tumors; (4) AR expression was associated with PR and Ki-67 in ER negative tumors, but not in ER positive tumors; (5) AR expression was higher in ER positive subtypes (Luminal A, Luminal B and Luminal HER2 subtypes, 80%–86%) and lower in ER negative subtypes [HER2, triple negative (TN), and TN EFGR positive subtypes; 52%–66%], with over 50% of TN tumors expressing AR.

Conclusion: More breast carcinomas express AR than ER and PR, including significant numbers of ER negative and TN tumors, for which AR could serve as a potential therapeutic target.


Downloads

PDF  (2.02 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML






What Your Colleagues Say About Breast Cancer: Basic and Clinical Research
testimonial_image
The submission process for manuscript publication in Breast Cancer: Basic and Clinical Research is as easy as A,B,C!  Any minor hiccups I encountered were quickly addressed by Libertas' expert staff via prompt emails, and the timelines between initial submission and publication are surely the shortest on record!  I will definitely be submitting future manuscripts to this journal, and look forward to working with their professional and expert team.
Dr Maggie Laidlaw (Nutrasource Diagnostics Inc, Guelph, Ontario, Canada)
More Testimonials

Quick Links


New article and journal news notification services